Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma.

Lanzi C, Dal Bo L, Favini E, Tortoreto M, Beretta GL, Arrighetti N, Zaffaroni N, Cassinelli G.

Cancers (Basel). 2019 Mar 22;11(3). pii: E408. doi: 10.3390/cancers11030408.

2.

miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition.

El Bezawy R, Tinelli S, Tortoreto M, Doldi V, Zuco V, Folini M, Stucchi C, Rancati T, Valdagni R, Gandellini P, Zaffaroni N.

J Exp Clin Cancer Res. 2019 Feb 4;38(1):51. doi: 10.1186/s13046-019-1060-z.

3.

[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.

Raccagni I, Belloli S, Valtorta S, Stefano A, Presotto L, Pascali C, Bogni A, Tortoreto M, Zaffaroni N, Daidone MG, Russo G, Bombardieri E, Moresco RM.

PLoS One. 2018 May 23;13(5):e0197754. doi: 10.1371/journal.pone.0197754. eCollection 2018.

4.

Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.

Cassinelli G, Dal Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, De Cesare M, Lecis D, Scanziani E, Minoli L, Naggi A, Vlodavsky I, Zaffaroni N, Lanzi C.

Cancer Lett. 2018 Feb 28;415:187-197. doi: 10.1016/j.canlet.2017.12.009. Epub 2017 Dec 7.

PMID:
29225052
5.

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.

Rossini A, Zunino F, Ruggiero G, De Cesare M, Cominetti D, Tortoreto M, Lanzi C, Cassinelli G, Zappasodi R, Tripodo C, Gulino A, Zaffaroni N, Di Nicola M.

Hematol Oncol. 2018 Feb;36(1):360-362. doi: 10.1002/hon.2466. Epub 2017 Jul 21. No abstract available.

PMID:
28730742
6.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
7.

Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L.

Oncoimmunology. 2016 Sep 20;5(11):e1234571. doi: 10.1080/2162402X.2016.1234571. eCollection 2016.

8.

Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response.

Valtorta S, Moro M, Prisinzano G, Bertolini G, Tortoreto M, Raccagni I, Pastorino U, Roz L, Sozzi G, Moresco RM.

J Nucl Med. 2017 Jan;58(1):42-47. doi: 10.2967/jnumed.116.176404. Epub 2016 Oct 20.

9.

Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.

Fiorentini C, Fragni M, Perego P, Vezzoli S, Bonini SA, Tortoreto M, Galli D, Claps M, Tiberio GA, Terzolo M, Missale C, Memo M, Procopio G, Zaffaroni N, Berruti A, Sigala S.

J Clin Endocrinol Metab. 2016 Dec;101(12):4594-4602. Epub 2016 Sep 14.

10.

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.

Cassinelli G, Favini E, Dal Bo L, Tortoreto M, De Maglie M, Dagrada G, Pilotti S, Zunino F, Zaffaroni N, Lanzi C.

Oncotarget. 2016 Jul 26;7(30):47848-47863. doi: 10.18632/oncotarget.10292.

11.

Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.

Lopergolo A, Perrone R, Tortoreto M, Doria F, Beretta GL, Zuco V, Freccero M, Borrello MG, Lanzi C, Richter SN, Zaffaroni N, Folini M.

Oncotarget. 2016 Aug 2;7(31):49649-49663. doi: 10.18632/oncotarget.10105.

12.

TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site.

Rivoltini L, Chiodoni C, Squarcina P, Tortoreto M, Villa A, Vergani B, Bürdek M, Botti L, Arioli I, Cova A, Mauri G, Vergani E, Bianchi B, Della Mina P, Cantone L, Bollati V, Zaffaroni N, Gianni AM, Colombo MP, Huber V.

Clin Cancer Res. 2016 Jul 15;22(14):3499-512. doi: 10.1158/1078-0432.CCR-15-2170. Epub 2016 Mar 4.

13.

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.

Le Noci V, Tortoreto M, Gulino A, Storti C, Bianchi F, Zaffaroni N, Tripodo C, Tagliabue E, Balsari A, Sfondrini L.

Oncoimmunology. 2015 May 27;4(10):e1040214. eCollection 2015 Oct.

14.

Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.

Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, Tortoreto M, Milione M, Ferracini R, Mariani L, Pastorino U, Roato I, Sozzi G, Roz L.

Cancer Res. 2015 Sep 1;75(17):3636-49. doi: 10.1158/0008-5472.CAN-14-3781. Epub 2015 Jul 3.

15.

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.

Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P.

Biochem Pharmacol. 2015 Mar 15;94(2):79-90. doi: 10.1016/j.bcp.2015.01.002. Epub 2015 Jan 16.

PMID:
25600908
16.

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.

Zappasodi R, Ruggiero G, Guarnotta C, Tortoreto M, Tringali C, Cavanè A, Cabras AD, Castagnoli L, Venerando B, Zaffaroni N, Gianni AM, De Braud F, Tripodo C, Pupa SM, Di Nicola M.

Blood. 2015 Mar 12;125(11):1768-71. doi: 10.1182/blood-2014-07-590034. Epub 2015 Jan 8.

17.

XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).

Gravina GL, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, Landesman Y, McCauley D, Kauffman M, Shacham S, Zaffaroni N, Festuccia C.

J Hematol Oncol. 2014 Oct 5;7:46. doi: 10.1186/1756-8722-7-46.

18.

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.

Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N.

Eur J Cancer. 2014 Nov;50(17):3021-8. doi: 10.1016/j.ejca.2014.09.004. Epub 2014 Sep 27.

PMID:
25269954
19.

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E.

Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015. Epub 2014 Mar 27.

20.

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.

Zappasodi R, Cavanè A, Iorio MV, Tortoreto M, Guarnotta C, Ruggiero G, Piovan C, Magni M, Zaffaroni N, Tagliabue E, Croce CM, Zunino F, Gianni AM, Di Nicola M.

Int J Cancer. 2014 Nov 1;135(9):2034-45. doi: 10.1002/ijc.28852. Epub 2014 Mar 26. Erratum in: Int J Cancer. 2017 Nov 1;141(9):E6.

21.

Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.

Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C.

J Clin Endocrinol Metab. 2014 Feb;99(2):498-509. doi: 10.1210/jc.2013-2574. Epub 2013 Nov 25.

PMID:
24276455
22.

Maspin influences response to doxorubicin by changing the tumor microenvironment organization.

Triulzi T, Ratti M, Tortoreto M, Ghirelli C, Aiello P, Regondi V, Di Modica M, Cominetti D, Carcangiu ML, Moliterni A, Balsari A, Casalini P, Tagliabue E.

Int J Cancer. 2014 Jun 15;134(12):2789-97. doi: 10.1002/ijc.28608. Epub 2013 Nov 30.

23.

Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.

Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, Casali PG.

Clin Cancer Res. 2013 Sep 15;19(18):5192-201. doi: 10.1158/1078-0432.CCR-13-0776. Epub 2013 Jul 25.

24.

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F.

Biochem Pharmacol. 2013 May 15;85(10):1424-32. doi: 10.1016/j.bcp.2013.02.023. Epub 2013 Mar 1.

PMID:
23466421
25.

Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.

Sfondrini L, Sommariva M, Tortoreto M, Meini A, Piconese S, Calvaruso M, Van Rooijen N, Bonecchi R, Zaffaroni N, Colombo MP, Tagliabue E, Balsari A.

Int J Cancer. 2013 Jul 15;133(2):383-93. doi: 10.1002/ijc.28028. Epub 2013 Feb 12.

26.

REST controls self-renewal and tumorigenic competence of human glioblastoma cells.

Conti L, Crisafulli L, Caldera V, Tortoreto M, Brilli E, Conforti P, Zunino F, Magrassi L, Schiffer D, Cattaneo E.

PLoS One. 2012;7(6):e38486. doi: 10.1371/journal.pone.0038486. Epub 2012 Jun 11. Erratum in: PLoS One. 2015;10(9):e0139645.

27.

Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.

Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM.

Mol Oncol. 2012 Aug;6(4):458-72. doi: 10.1016/j.molonc.2012.03.003. Epub 2012 Apr 19.

28.

Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells.

Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L.

J Biomed Biotechnol. 2012;2012:568567. doi: 10.1155/2012/568567. Epub 2012 Apr 4. Review.

29.

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, Cominetti D, Zaffaroni N, Orlandi A, Passeri D, Meco D, Di Francesco AM, Riccardi R, Bucci F, Pisano C, Zunino F.

Biochem Pharmacol. 2012 Jul 15;84(2):163-71. doi: 10.1016/j.bcp.2012.04.005. Epub 2012 Apr 13.

PMID:
22525722
30.

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

Zappasodi R, Bongarzone I, Ghedini GC, Castagnoli L, Cabras AD, Messina A, Tortoreto M, Tripodo C, Magni M, Carlo-Stella C, Gianni AM, Pupa SM, Di Nicola M.

Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.

31.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
32.

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.

Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y.

Clin Cancer Res. 2011 Mar 15;17(6):1382-93. doi: 10.1158/1078-0432.CCR-10-2476. Epub 2011 Jan 21.

33.

Pre-clinical and clinical significance of heparanase in Ewing's sarcoma.

Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I, Zunino F.

J Cell Mol Med. 2011 Sep;15(9):1857-64. doi: 10.1111/j.1582-4934.2010.01190.x.

34.

Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.

Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F.

Clin Cancer Res. 2010 Aug 1;16(15):3944-53. doi: 10.1158/1078-0432.CCR-10-0964. Epub 2010 Jun 18.

35.

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.

Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM.

J Cell Physiol. 2010 Oct;225(1):256-65. doi: 10.1002/jcp.22257.

PMID:
20506359
36.

Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines.

Gasparini P, Bertolini G, Binda M, Magnifico A, Albano L, Tortoreto M, Pratesi G, Facchinetti F, Abolafio G, Roz L, Tagliabue E, Daidone MG, Sozzi G.

Cancer Lett. 2010 Oct 28;296(2):206-15. doi: 10.1016/j.canlet.2010.04.009.

PMID:
20435407
37.

Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells.

Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, Pratesi G, Cossa G, Perego P, Daidone MG, Alison MR, Parmiani G, Rivoltini L, Castelli C.

J Invest Dermatol. 2010 Jul;130(7):1877-86. doi: 10.1038/jid.2010.69. Epub 2010 Apr 8.

38.

In vivo effects of rosiglitazone in a human neuroblastoma xenograft.

Cellai I, Petrangolini G, Tortoreto M, Pratesi G, Luciani P, Deledda C, Benvenuti S, Ricordati C, Gelmini S, Ceni E, Galli A, Balzi M, Faraoni P, Serio M, Peri A.

Br J Cancer. 2010 Feb 16;102(4):685-92. doi: 10.1038/sj.bjc.6605506. Epub 2010 Jan 12.

39.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

40.

Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.

Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, Bucci F, Pisano C, Zunino F.

Biochem Pharmacol. 2010 Feb 15;79(4):535-41. doi: 10.1016/j.bcp.2009.09.012.

PMID:
19765546
41.

Pharmacogenomics and analogues of the antitumour agent N6-isopentenyladenosine.

Colombo F, Falvella FS, De Cecco L, Tortoreto M, Pratesi G, Ciuffreda P, Ottria R, Santaniello E, Cicatiello L, Weisz A, Dragani TA.

Int J Cancer. 2009 May 1;124(9):2179-85. doi: 10.1002/ijc.24168.

42.

Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.

Pratesi G, Petrangolini G, Tortoreto M, Addis A, Zunino F, Calcaterra C, Merlo A, Tagliabue E, Menard S, Balsari A.

J Immunother. 2008 Jul-Aug;31(6):537-44. doi: 10.1097/CJI.0b013e31817c37ff.

PMID:
18528301
43.

Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft.

Petrangolini G, Tortoreto M, Perego P, Carenini N, De Cesare M, Balsari A, Zunino F, Pratesi G.

Cancer Biol Ther. 2008 Apr;7(4):596-601. Epub 2008 Jan 9.

PMID:
18364568
44.

Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.

Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, Misiano P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2008 Jan;324(1):15-22. Epub 2007 Oct 1.

PMID:
17909082
45.

Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.

Beretta GL, Petrangolini G, De Cesare M, Pratesi G, Perego P, Tinelli S, Tortoreto M, Zucchetti M, Frapolli R, Bello E, Manzotti C, Fontana G, Bombardelli E, Battaglia A, Samorì C, Zunino F.

Cancer Res. 2006 Nov 15;66(22):10976-82.

46.

Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.

Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F.

Mol Cancer Ther. 2006 Sep;5(9):2388-97.

47.

Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.

Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F.

Biochem Pharmacol. 2006 Aug 14;72(4):405-14. Epub 2006 Jun 6.

PMID:
16756963
48.

Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.

Petrangolini G, Supino R, Pratesi G, Dal Bo L, Tortoreto M, Croce AC, Misiano P, Belfiore P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2006 Sep;318(3):939-46. Epub 2006 May 19.

PMID:
16714402
49.

Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.

Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, Selleri S, Rumio C, Menard S, Balsari A.

Cancer Res. 2005 Jul 15;65(14):6388-93.

50.

Biocompatibility and tissue interactions of a new filler material for medical use.

Zarini E, Supino R, Pratesi G, Laccabue D, Tortoreto M, Scanziani E, Ghisleni G, Paltrinieri S, Tunesi G, Nava M.

Plast Reconstr Surg. 2004 Sep 15;114(4):934-42.

PMID:
15468401

Supplemental Content

Loading ...
Support Center